Cited by 287Substance Abuse Treatment and OutcomesAlcohol Consumption and Health EffectsSmoking Behavior and Cessation

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence

Open access

Litten, Raye Z., Ryan, Megan L., Fertig, Joanne B., Falk, Daniel E., Johnson, Bankole, Dunn, Kelly E., Green, Alan I., Pettinati, Helen M., Ciraulo, Domenic A., Sarid-Segal, Ofra, Kampman, Kyle, Brunette, Mary F., Strain, Eric C., Tiouririne, Nassima A., Ransom, Janet, Scott, Charles, Stout, Robert·2013·Journal of Addiction Medicine

DOI 10.1097/adm.0b013e31829623f4PMC PMC3914416

Open this paper in CoChat — free account

Abstract

OBJECTIVES: To assess the efficacy and safety of varenicline (Chantix) for the treatment of alcohol dependence. Varenicline is a partial α4β2 nicotinic acetylcholine agonist approved by the Food and Drug Administration for smoking cessation. It has reduced drinking in animal studies and in small studies of humans who were both heavy drinkers and smokers. This is the first multisite clinical trial of varenicline in a population of smokers and nonsmokers with alcohol dependence. METHODS: Men and women (n = 200) meeting the criteria for alcohol dependence were recruited across 5 clinical sites. Patients received double-blind varenicline or placebo and a computerized behavioral intervention. Varenicline was titrated during the first week to 2 mg/d, which was maintained during weeks 2 to 13. RESULTS: The varenicline group had significantly lower weekly percent heavy drinking days (primary outcome) (adjusted mean difference = 10.4), drinks per day, drinks per drinking day, and alcohol craving compared with the placebo group (P < 0.05). The average treatment effect on alcohol use was similar for smokers and nonsmokers. Varenicline was well-tolerated; adverse events were expected and mild. CONCLUSIONS: Varenicline significantly reduced alcohol consumption and craving, making it a potentially viable option for the treatment of alcohol dependence.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/adm.0b013e31829623f4

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Untitled work
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Untitled work
(1998) · PubMed · Cited by 10,216
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655
A power primer.
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Timeline Follow-Back
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870

Show all 47 references

Sorted by citations

Items 101–200 of 287

Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse, T. L., Pittman, B. P., Shi, J. M., Tetrault, J. M., Coppola, S., & McKee, S. A. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000208 · Cited by 23
An exploratory evaluation of Take Control : A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder
Devine, E. G., Ryan, M. L., Falk, D. E., Fertig, J. B., & Litten, R. Z. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.08.006 · Cited by 23
Self-citation
Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats
Söderpalm, B., Danielsson, K., de Bejczy, A., Adermark, L., & Ericson, M. (2019) · Addiction Biology · doi:10.1111/adb.12807 · Cited by 23
The Effect of Varenicline on the Neural Processing of Fearful Faces and the Subjective Effects of Alcohol in Heavy Drinkers
Gowin, J. L., Vatsalya, V., Westman, J. G., Schwandt, M. L., Bartlett, S. E., Heilig, M. A., Momenan, R., & Ramchandani, V. A. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13046 · Cited by 22
Different dopamine tone in ethanol high‐ and low‐consuming Wistar rats
Ericson, M., Ulenius, L., Andrén, A., Jönsson, S., Adermark, L., & Söderpalm, B. (2019) · Addiction Biology · doi:10.1111/adb.12761 · Cited by 22
Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future
Cannella, N., Ubaldi, M., Masi, A., Bramucci, M., Roberto, M., Bifone, A., & Ciccocioppo, R. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.014 · Cited by 24
Association of Syndemic Unhealthy Alcohol Use, Smoking, and Depressive Symptoms on Incident Cardiovascular Disease among Veterans With and Without HIV-Infection
Chichetto, N. E., Kundu, S., Freiberg, M. S., Koethe, J. R., Butt, A. A., Crystal, S., So-Armah, K. A., Cook, R. L., Braithwaite, R. S., Justice, A. C., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03327-4 · Cited by 20
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold, K. W., Zweben, A., Fucito, L. M., Piepmeier, M. E., Muvvala, S. B., Wu, R., Gueorguieva, R. V., & O’Malley, S. S. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13994 · Cited by 21
Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials
Oon‐arom, A., Likhitsathain, S., & Srisurapanont, M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107631 · Cited by 21
Antismoking agents do not contribute synergistically to semaglutide’s ability to reduce alcohol intake in rats
Aranäs, C., Blid Sköldheden, S., & Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180512 · Cited by 20
An acetylcholine‐dopamine interaction in the nucleus accumbens and its involvement in ethanol's dopamine‐releasing effect
Loftén, A., Adermark, L., Ericson, M., & Söderpalm, B. (2020) · Addiction Biology · doi:10.1111/adb.12959 · Cited by 19
Combined Pharmacotherapies for the Management of Alcoholism: Rationale and Evidence to Date
Lee, M. R., & Leggio, L. (2014) · CNS Drugs · doi:10.1007/s40263-013-0137-z · Cited by 20
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme
van den Brink, W., Strang, J., Gual, A., Sørensen, P. S., Jensen, T., & Mann, K. F. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1011619 · Cited by 20
“Killing Two Birds with One Stone”: Alcohol Use Reduction Interventions with Potential Efficacy at Enhancing Self-control
Leeman, R. F., Bogart, D., Fucito, L. M., & Boettiger, C. A. (2014) · Current Addiction Reports · doi:10.1007/s40429-013-0008-1 · Cited by 19
Clinical Neuroscience of Addiction: Similarities and Differences Between Alcohol and Other Drugs
Karoly, H. C., YorkWilliams, S. L., & Hutchison, K. E. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12884 · Cited by 19
Advancing Pharmacotherapy Development from Preclinical Animal Studies
Egli, M. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2017_85 · Cited by 19
From gene networks to drugs: systems pharmacology approaches for AUD
Ferguson, L. B., Harris, R. A., & Mayfield, R. D. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4855-2 · Cited by 19
Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats
Scuppa, G., Cippitelli, A., Toll, L., Ciccocioppo, R., & Ubaldi, M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.002 · Cited by 19
Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.
Roberts, W., & McKee, S. A. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000161 · Cited by 18
Alcohol use disorder severity moderates clinical response to varenicline
Donato, S., Green, R., & Ray, L. A. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14674 · Cited by 18
Mechanisms underlying sleep–wake disturbances in alcoholism: Focus on the cholinergic pedunculopontine tegmentum
Knapp, C. M., Ciraulo, D. A., & Datta, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.029 · Cited by 19
Self-citation
Pharmacologic treatment of alcoholism
Anton, R. F., Schacht, J. P., & Book, S. W. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00030-6 · Cited by 21
Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms
Roberts, W., Verplaetse, T. L., Moore, K. E., Oberleitner, L., Picciotto, M. R., & McKee, S. A. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699618 · Cited by 18
Pharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17
Short-term, low-dose varenicline administration enhances information processing speed in methamphetamine-dependent users
Kalechstein, A. D., Mahoney, J. J., Verrico, C. D., & Garza, R. D. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.045 · Cited by 17
Pharmacological Treatment of Alcohol Cravings
Marin, M. C. D., Pedro, M. O. P., Perrotte, G., Martins-da-Silva, A. S., Lassi, D. L. S., Blaas, I. K., Castaldelli, F. I., dos Santos, M. B. B., Kortas, G. T., Campos, M. W., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13081206 · Cited by 17
Alcohol-Induced Increases in Inflammatory Cytokines Are Attenuated by Nicotine in Region-Selective Manner in Male Rats
Kalejaiye, O., Getachew, B., Ferguson, C. L., Taylor, R. E., & Tizabi, Y. (2017) · Journal of Drug and Alcohol Research · doi:10.4303/jdar/236036 · Cited by 17
Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial
Briones, M. S., SHOPTAW, S. J., Cook, R., Worley, M. J., Swanson, A., Moody, D. E., Fang, W. B., TSUANG, J. W., Furst, B. A., & Heinzerling, K. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.023 · Cited by 18
Agonist and antagonist effects of cytisine in vivo
Radchenko, E. V., Драволина, О. А., & Bespalov, A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.019 · Cited by 19
Smoking As an Outcome Moderator In the Treatment of Alcohol Use Disorders
van Amsterdam, J., & van den Brink, W. (2022) · Alcohol and Alcoholism · doi:10.1093/alcalc/agac027 · Cited by 16
Stress‐related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective
Heilig, M. A. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13636 · Cited by 19
Pharmacological Treatments for Alcohol Use Disorder: Considering the Role of Sex and Gender
Kirsch, D. E., Belnap, M. A., Burnette, E. M., Grodin, E. N., & Ray, L. A. (2024) · Current Addiction Reports · doi:10.1007/s40429-023-00535-x · Cited by 16
Alcohol and the dopamine system
Söderpalm, B., & Ericson, M. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.02.003 · Cited by 16
Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings
Verplaetse, T. L., Pittman, B. P., Shi, J. M., Tetrault, J. M., Coppola, S., & McKee, S. A. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13110 · Cited by 16
The effect of varenicline on binge-like ethanol consumption in mice is β4 nicotinic acetylcholine receptor-independent
Patkar, O. L., Belmer, A., Tarren, J. R., Holgate, J. Y., & Bartlett, S. E. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.09.048 · Cited by 17
Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement
Martin, R. A., Rohsenow, D. J., & Tidey, J. W. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.06.005 · Cited by 17
Differential patterns of alcohol and nicotine intake: Combined alcohol and nicotine binge consumption behaviors in mice
DeBaker, M. C., Robinson, J. M., Moen, J. K., Wickman, K. D., & Lee, A. M. (2019) · Alcohol · doi:10.1016/j.alcohol.2019.09.006 · Cited by 16
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 15
Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial
Burnette, E. M., Baskerville, W., Grodin, E. N., & Ray, L. A. (2020) · Trials · doi:10.1186/s13063-020-04670-y · Cited by 15
Methadone’s effect on nAChRs—a link between methadone use and smoking?
Talka, R., Tuominen, R. K., & Salminen, O. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.031 · Cited by 15
Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression
Phimarn, W., Sakhancord, R., Paitoon, P., Saramunee, K., & Sungthong, B. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054091 · Cited by 14
Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta‐analysis
Kotake, K., Hosokawa, T., Tanaka, M., So, R., Banno, M., Kataoka, Y., Shiroshita, A., & Hashimoto, Y. (2024) · Addiction · doi:10.1111/add.16421 · Cited by 14
Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder
Zawertailo, L. A., Ivanova, A., Ng, G., Foll, B. L., & Selby, P. L. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001172 · Cited by 14
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats
Chandler, C. M., Maggio, S. E., Peng, H., Nixon, K., & Bardo, M. T. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107988 · Cited by 14
Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder
Mason, B. J. (2022) · Alcohol research · doi:10.35946/arcr.v42.1.11 · Cited by 15
The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice
Miller, C. N., Ruggery, C., & Kamens, H. M. (2018) · Alcohol · doi:10.1016/j.alcohol.2018.11.006 · Cited by 14
Does Reducing Drinking in Patients with Unhealthy Alcohol Use Improve Pain Interference, Use of Other Substances, and Psychiatric Symptoms?
Caniglia, E. C., Stevens, E. R., Khan, M. R., Young, K. E., Ban, K. F., Marshall, B. D. L., Chichetto, N. E., Gaither, J. R., Crystal, S., Edelman, E. J., et al. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14455 · Cited by 14
Varenicline provokes impulsive action by stimulating α4β2 nicotinic acetylcholine receptors in the infralimbic cortex in a nicotine exposure status-dependent manner
Ohmura, Y., Sasamori, H., Tsutsui‐Kimura, I., Izumi, T., Yoshida, T., & Yoshioka, M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.01.002 · Cited by 13
Co‐Administration of Low‐Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol‐Preferring (P) Rats
Nicholson, E. R., Dilley, J. E., & Froehlich, J. C. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13577 · Cited by 14
Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers
Yardley, M. M., Mirbaba, M., & Ray, L. A. (2015) · CNS Drugs · doi:10.1007/s40263-015-0284-5 · Cited by 15
Technology-Based Interventions and Trainings to Reduce the Escalation and Impact of Alcohol Problems
Resko, S. M., Brown, S., Lister, J. J., Ondersma, S. J., Cunningham, R. M., & Walton, M. A. (2017) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2017.1304948 · Cited by 14
The nicotinic receptor drug sazetidine-A reduces alcohol consumption in mice without affecting concurrent nicotine consumption
Touchette, J. C., Maertens, J. J., Mason, M. M., O’Rourke, K. Y., & Lee, A. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.019 · Cited by 13
The Link between Alcohol Consumption and Kidney Injury
Yokus, B., Maccioni, L., Fu, L., Haskó, G., Nagy, L. E., Gao, B., & Pacher, P. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.05.011 · Cited by 15
Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol‐Preferring (P) Rats
Froehlich, J. C., Nicholson, E. R., Dilley, J. E., Filosa, N. J., Rademacher, L. C., & Smith, T. N. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13432 · Cited by 12
Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats
Maggio, S. E., Saunders, M. A., Baxter, T. A., Nixon, K., Prendergast, M., Zheng, G., Crooks, P. A., Dwoskin, L. P., Slack, R. D., Newman, A. H., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4853-4 · Cited by 12
Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study
Roberts, W., Shi, J. M., Tetrault, J. M., & McKee, S. A. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000392 · Cited by 12
The Effects of Long‐Term Varenicline Administration on Ethanol and Sucrose Seeking and Self‐Administration in Male P Rats
Czachowski, C. L., Froehlich, J. C., & DeLory, M. J. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13562 · Cited by 11
Efficacy of Varenicline in Patients With Severe Alcohol Dependence
Pfeifer, P., & Fehr, C. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001056 · Cited by 11
Design of a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia
Tindle, H. A., Freiberg, M. S., Gnatienko, N., Blokhina, E. A., Cheng, D. M., Yaroslavtseva, T. V., Bendiks, S., Winter, M. R., Krupitsky, E. M., & Samet, J. H. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100625 · Cited by 11
Pharmakotherapie der Alkoholentwöhnung: Update und neue Entwicklungen
Soyka, M., & Rösner, S. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00954-5 · Cited by 13
Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels
Nieto, S. J., Enders, C. K., Witkiewitz, K. A., O’Malley, S. S., & Ray, L. A. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14953 · Cited by 10
Smoking Cessation for Those Pursuing Recovery from Substance Use Disorders
Derefinko, K. J., García, F. I. S., & Sumrok, D. D. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.014 · Cited by 10
Searching for Personalized Medicine for Binge Drinking Smokers: Smoking Cessation Using Varenicline, Nicotine Patch, or Combination Nicotine Replacement Therapy
Kaye, J. T., Johnson, A. L., Baker, T. B., Piper, M. E., & Cook, J. W. (2020) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2020.81.426 · Cited by 11
Therapeutic targets in alcohol-associated liver disease: progress and challenges
Adekunle, A. D., Adejumo, A., & Singal, A. K. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231170946 · Cited by 14
Primary Care Management of Alcohol Misuse
Berger, D. B., & Bradley, K. A. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.05.004 · Cited by 10
Drug effects on multiple and concurrent schedules of ethanol‐ and food‐maintained behaviour: context‐dependent selectivity
Ginsburg, B. C., & Lamb, R. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12707 · Cited by 10
Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption
Wang, J., Blasio, A., Chapman, H. L., Doebelin, C., Liaw, V., Kuryatov, A., Giovanetti, S. M., Lindstrom, J. M., Li, L., Cameron, M. D., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0475-8 · Cited by 10
Alcohol Medications Development: Advantages and Caveats of Government/Academia Collaborating with the Pharmaceutical Industry
Litten, R. Z., Ryan, M., Falk, D. E., & Fertig, J. B. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12357 · Cited by 9
Self-citation
Relative Potency of Varenicline or Fluvoxamine to Reduce Responding for Ethanol Versus Food Depends on the Presence or Absence of Concurrently Earned Food
Ginsburg, B. C., & Lamb, R. J. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12285 · Cited by 9
Unhealthy Alcohol Use
Holt, S. R., & Tetrault, J. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.02.003 · Cited by 9
The Human Laboratory and Drug Development in Alcohol Use Disorder: Recent Updates
Chukwueke, C. C., & Foll, B. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_12 · Cited by 9
Drug addiction co-morbidity with alcohol: Neurobiological insights
McGinn, M. A., Pantazis, C. B., Tunstall, B. J., Marchette, R. C. N., Carlson, E. R., Said, N., Koob, G. F., & Vendruscolo, L. F. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2020.11.002 · Cited by 11
Alcohol-Associated Liver Disease: Managing the Dual Pathology of Liver Disease and of Alcohol Use Disorder
Arab, J. P., Louvet, A., Thiele, M. S., Winder, G. S., Wong, R. J., & Singal, A. K. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.042 · Cited by 8
Translating Alcohol Research: Opportunities and Challenges
Batman, A. M. (2015) · Alcohol research · doi:10.35946/arcr.v37.1.01 · Cited by 8
The role of nicotinic receptors in alcohol consumption
Kamens, H. M., Flarend, G., & Horton, W. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106705 · Cited by 8
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers
Grodin, E. N., Burnette, E. M., Green, R., Lim, A. C., Miotto, K. A., & Ray, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108825 · Cited by 8
Underutilization of Pharmacotherapy for Treatment of Alcohol Use Disorders Part II-Results from a Survey of Practices among North Carolina Mental Health Providers and Brief Review of Efficacy of Available Pharmacotherapies
Penders, T. M., Wuensch, K. L., Davis, J. S., Elnagar, K., & Stanciu, C. N. (2017) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000285 · Cited by 8
A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking
Froehlich, J. C., Fischer, S. M., Nicholson, E. R., Dilley, J. E., Filosa, N. J., Smith, T. N., & Rademacher, L. C. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13326 · Cited by 7
The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats
Olsson, Y., Lidö, H. H., Ademar, K., Cadeddu, D., Ericson, M., & Söderpalm, B. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02701-x · Cited by 8
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts, W., Ralevski, E., Verplaetse, T. L., McKee, S. A., & Petrakis, I. L. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.08.015 · Cited by 7
A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial
Ray, L. A., Baskerville, W., Nieto, S. J., Grodin, E. N., Enders, C. K., Kady, A., Meredith, L. R., Gillis, A. J., Leventhal, A. M., Ho, D., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06504-6 · Cited by 7
Intermittent Access To Ethanol Induces Escalated Alcohol Consumption In Primates
Lindell, S. G., Schwandt, M. L., Suomi, S. J., Rice, K. C., Heilig, M. A., & Barr, C. S. (2017) · Journal of Addictive Behaviors Therapy & Rehabilitation · doi:10.4172/2324-9005.1000163 · Cited by 7
Nonsmoking after simultaneous alcohol abstinence and smoking cessation program was associated with better drinking status outcome in Japanese alcohol-dependent men: A prospective follow-up study
Yokoyama, A., Kimura, M., Yoshimura, A., Matsushita, S., Yoneda, J., Maesato, H., Komoto, Y., Nakayama, H., Sakuma, H., Yumoto, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282992 · Cited by 6
Varenicline for the Treatment of Cocaine Dependence
Lynch, K. G., Plebani, J. G., Spratt, K. A., Morales, M., Tamminga, M. A., Feibush, P., & Kampman, K. M. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000842 · Cited by 5
Self-citation
Are medication effects on subjective response to alcohol and cue-induced craving associated? A meta regression study
Ray, L. A., Nieto, S. J., Meredith, L. R., Burnette, E. M., Donato, S., Magill, M., & Du, H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06409-4 · Cited by 6
Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder
Lékó, A. H., Farokhnia, M., & Leggio, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_16 · Cited by 6
Prospective Association Between Tobacco Use and at-Risk Alcohol Consumption Among Swedish Adolescents: Outlining the Influence of Tobacco Product, Frequency of Use and Gender in the LoRDIA Cohort
Andersson, J., Berglund, K. J., Irmel, R., & Adermark, L. (2024) · Tobacco Use Insights · doi:10.1177/1179173x241298524 · Cited by 6
Contribution of Noradrenaline, Serotonin, and the Basolateral Amygdala to Alcohol Addiction: Implications for Novel Pharmacotherapies for AUDs
Patkar, O. L., Belmer, A., & Bartlett, S. E. (2016) · InTech eBooks · doi:10.5772/62843 · Cited by 6
Enhancement of alcohol aversion by the nicotinic acetylcholine receptor drug sazetidine‐A
Touchette, J. C., Moen, J. K., Robinson, J. M., & Lee, A. M. (2020) · Addiction Biology · doi:10.1111/adb.12908 · Cited by 6
Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy
Guiraud, J., Spanagel, R., & van den Brink, W. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.03.005 · Cited by 5
Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trial
Söderpalm, B., Lidö, H. H., Franck, J., Håkansson, A., Lindqvist, D., Heilig, M. A., Guterstam, J., Samuelson, M., Askerup, B., Nilsson‐Wallmark, C., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101310 · Cited by 5
Free‐access intravenous alcohol self‐administration in social drinkers and individuals with alcohol use disorder: Evaluation of relationships with phosphatidylethanol and self‐reported alcohol consumption
Olsson, Y., Hodzic, K., Wass, C., Lidö, H. H., Stangl, B. L., O’Connor, S., Plawecki, M. H., Ramchandani, V. A., Söderpalm, B., & Jerlhag, E. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15132 · Cited by 5
Systematic review of patient contribution to the development of alcohol craving measurements
Zeganadin, L., López‐Castromán, J., Auriacombe, M., & Luquiens, A. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15409 · Cited by 5
Recruitment Techniques for Alcohol Pharmacotherapy Clinical Trials
Tompkins, D. A., Sides, J. A., Harrison, J. A., & Strain, E. C. (2014) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000047 · Cited by 5
Self-citation
Molecular Imaging Studies of Alcohol Use Disorder
Bach, P., de Timary, P., Gründer, G., & Cumming, P. D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_414 · Cited by 5
An integrated behavioural intervention combined with varenicline for heavy-drinking smokers: a randomized pilot study
Fucito, L. M., Wu, R., O’Malley, S. S., Hanrahan, T. H., Ikomi, J. T., Muvvala, S. B., Carroll, K. M., & Gueorguieva, R. V. (2020) · The Journal of Smoking Cessation · doi:10.1017/jsc.2020.13 · Cited by 5
Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article
Litten, R. Z., Falk, D. E., O’Malley, S. S., Witkiewitz, K. A., Mann, K. F., & Anton, R. F. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13411 · Cited by 5
Self-citation
Changes in Alcohol Consumption During a Stop-Smoking Attempt and Differences Between Smokers Using Nicotine Replacement and Smokers Using Varenicline
Przulj, D., Hájek, P., Snuggs, S. J., & McRobbie, H. J. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx105 · Cited by 4
Nicotinic and muscarinic acetylcholine receptor antagonism dose-dependently decreases sign- but not goal-tracking behavior in male rats
Gheidi, A., Fitzpatrick, C. J., Gregory, J. D., & Morrow, J. D. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06328-4 · Cited by 6
Novel Therapy for Nicotine Addiction in Alcohol Dependent Rats
Boules, M., Li, N. M. Z., & Richelson, S. C. E. (2013) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000161 · Cited by 4

Authors: Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., Kampman, K., Brunette, M. F., Strain, E. C., Tiouririne, N. A., Ransom, J., Scott, C., & Stout, R.
Affiliations: Boston University (US)
National Institutes of Health (US)
University of Virginia (US)
Dartmouth College (US)
University of Pennsylvania (US)
Johns Hopkins University (US)
Fast Track Drugs and Biologics (US)
Pacific Institute For Research and Evaluation (US)
Corresponding author: Litten, Raye Z.
ORCID: Litten, Raye Z.
Falk, Daniel E.
Johnson, Bankole
Dunn, Kelly E.
Green, Alan I.
Ciraulo, Domenic A.
Kampman, Kyle
Brunette, Mary F.
Strain, Eric C.
Tiouririne, Nassima A.
Ransom, Janet
Stout, Robert
Venue: Journal of Addiction Medicine
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-07
Volume: 7
Issue: 4
Pages: 277-286
ISSN: 1932-0620 (ISSN-L)
DOI: 10.1097/adm.0b013e31829623f4
PMC: PMC3914416
OpenAlex: W2006833508
Cited by: 287
References: 47
Citations by year: 2026: 7 · 2025: 15 · 2024: 10 · 2023: 25 · 2022: 9 · 2021: 40 · 2020: 21 · 2019: 24 · 2018: 25 · 2017: 26 · 2016: 26 · 2015: 25 · 2014: 26 · 2013: 7
FWCI: 20.40
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Addiction Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (4k24da023186-10)
U.S. Public Health Service (HHSN27200900005C)
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse (K24-DA023186)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275200900005C)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Keywords: varenicline, alcoholism, nicotinic agonists, alcohol craving, heavy drinking, smoking cessation, drug efficacy, drug safety
MeSH terms: Varenicline, Adult, Alcoholism, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Treatment Outcome, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks